sciclone pharmaceuticals inc board of directors contact us  site map   english board of directors jon s saxe jd jon s saxe has served as the chairman of sciclone’s board of directors since july  and as a director since august  mr saxe was president of pdl biopharma inc formerly protein design labs inc nasdaq pdli from  to early from  to  mr saxe was president of saxe associates inc consultants to venture capital firms and biotechnology diagnostic and pharmaceutical companies he was the president and ceo of synergen inc a biotechnology company acquired by amgen from  to  mr saxe is former vice president licensing and corporate development and head of patent law for hoffmannlaroche inc where he worked for almost  years mr saxe received his bsche from carnegie mellon university his jd from george washington university school of law and his llm from new york university school of law he serves as a director of other public and private companies including durect corporation and as chairman of vistagen therapeutics inc he also has broad experience as a board member in our industry including experience as an audit committee business development committee compensation committee nominating and governance committee member friedhelm blobel phd friedhelm blobel phd has served as our president chief executive officer and a director since june  from july  to  dr blobel was president chief executive officer and a director of gryphon therapeutics inc a south san franciscobased biopharmaceutical company prior to joining gryphon therapeutics in july  dr blobel spent more than two decades as an executive with the hoechst group and the boehringer mannheim group including responsibilities in the areas of diabetes and in vitro diagnostics his roles at these companies included group president of several product divisions chief technology officer and general manager in tokyo japan of a marketing and sales joint venture between boehringer and yamanouchi pharmaceuticals now astellas pharma inc senior vice president of research and development diabetes and patient care in mannheim germany as well as in indianapolis indiana dr blobel earned his doctorate degree “drrernat” a phd equivalent with a dissertation in biochemistry and microbiology from the university of hohenheim germany and holds an advanced degree in chemistry from the university of stuttgart germany dr blobel has spent his entire career in the pharmaceutical and biotechnology industry and brings to the board experience in general management research and development and product marketing and distribution nancy t chang phd nancy t chang phd has served as a director since september  since  dr chang has served as the president of apex enterprises inc an investment management company with a major focus on healthcare investments from  to  she was the chairperson and senior managing director of caduceus asia partners at orbimed advisors llc from  to  dr chang served as ffounder president and chairman of tanox inc which was sold to genentech in  prior to founding tanox dr chang held several leadership positions at centocor now a division of johnson and johnson she was also an associate professor at baylor college of medicine and before that she worked at the roche institute of molecular biology dr chang received her doctorate in biological chemistry from harvard university dr chang brings to the board deep industry and business expertise drawing on her scientific knowledge and her long history as a president and board member at a variety of public and private biopharmaceutical companies richard j hawkins richard j hawkins has served as a director since october  since  mr hawkins has been the president and chief executive officer of lumos pharma inc a privatelyheld company mr hawkins has served as the president and chief executive officer of id inc a privatelyheld company since  and as the chairman and ceo of labnow inc a privatelyheld company he founded that develops labonachip sensor technology to be used in pointofcare diagnostic testing systems since  from  to  mr hawkins co founded and served as director at corning biopro a protein contract manufacturing firm from  to  mr hawkins cofounded and served as chairman of sensus drug development which developed and received regulatory approval for somavert®  a growth hormone antagonist approved for the treatment of acromegaly and now marketed by pfizer in both the united states and europe in 8 mr hawkins founded pharmaco a clinical research organization cro that in  was merged with the predecessor of ppdpharmaco one of the largest cros in the world today mr hawkins has served as a member of the board of directors of cytori therapeutics inc since  mr hawkins graduated cum laude with a bs in biology from ohio university mr hawkins is an entrepreneur who has formed financed and operated multiple ventures in the pharmaceutical industry and he brings substantial experience to the board in clinical development as well as the management of growing enterprises gregg anthony lapointe gregg anthony lapointe has served as a director since march  mr lapointe is currently the chief executive officer of cerium pharmaceuticals inc a specialty pharmaceutical company from april 0 to march  mr lapointe served as chief executive officer of sigmatau pharmaceuticals inc a pharmaceutical company focused on rare disorders and the us whollyowned subsidiary of sigmatau finanziaria spa he served as chief operating officer of sigmatau pharmaceuticals inc from november  to march 0 mr lapointe is a certified public accountant in the united states and a chartered accountant in canada he holds a bachelor of commerce degree from concordia university of montreal a graduate diploma in public accountancy from mcgill university of montreal and an mba from duke university mr lapointe also serves on the boards of directors of soligenix inc and raptor pharmaceuticals corp mr lapointe brings to the board substantial experience in finance and management including operational experience as the ceo of a pharmaceutical development and sales organization simon li simon li was appointed a director in january  he is currently the chairman and chief executive officer of j w medical system ltd an affiliated company of biosensors international ltd from  to  mr li served in various positions at medtronic a global medical technology company including as the global officer and member of the executive committee of medtronic and president greater china and chairman of the board medtronicweigao jv prior to medtronic from  to 5 mr li served in various positions at johnson  johnson medical china including international vice president north asia  new business development asia pacific  strategic medical affairs asia pacific earlier in his career with jj he held the positions of international vice president north asia managing director china and hong kong and managing director china prior to jj mr li was president and chief operating officer of the convatec business with bristolmyers squibb in hong kong he also served as general manager of the pharmaceutical distributor yc woo  co ltd in hong kong he earned a bachelor of arts degree in social sciences from the university of hong kong an mba degree from henley management and an advanced emba from harvard business school mr li brings to the board international experience and perspective combined with substantial knowledge of emerging markets success in building profitable companies and experience in managing complex international business operations login  07 sciclone pharmaceuticals inc all rights reserved please read our disclaimer terms of use  notes regarding forward looking statements 。。    jon saxe  sciclone pharmaceuticals  inc  zoominfocom jon s saxe – lumos pharma company overview management team board of directors advisory board our offices pipeline clinical trials lum resources news contact jon s saxe independent about jon s saxe mr saxe has served as a director of over 5 companies and at present is a director of three public companies durect corporation nasdaq drrx vistagen nasdaqvtgn and sciclone pharmaceuticals inc nasdaqscln and private companies arbor vita arcuo medical armetheon cancer prevention pharmaceuticals  lumos pharma and trellis bioscience mr saxe is chairman of sciclone vista gen and vytacera he was president of pdl biopharma inc formerly protein design labs inc nasdaq pdli from  to  in  he was eir at institutional venture partners from  to  mr saxe was principal of saxe associates inc consultants to venture capital firms and biotechnology diagnostic and pharmaceutical companies from  to  he was the president and ceo of synergen inc a biotechnology company purchased by amgen prior to then mr saxe was vice president licensing and corporate development and head of patent law for hoffmannlaroche inc where he worked for  years mr saxe received a bsche from carnegie mellon university his jd from george washington university school of law his llm from new york university school of law and a certificate in business administration from duke university jon saxes phone number email address public records  spokeo contact us document script spokewidgetjsscript div classspokewidget datahostwwwspokecom datatypeperson dataide4cecfb datawidth dataheight datascrollno dataframebordernonediv div stylefontsize pta hrefhttpwwwspokecompeoplejonsaxee4cecfbjon saxea widget provided by a hrefhttpwwwspokecomspokeadiv public records our partner can help you find public records for jon more on some of spokes content providers become a spoke content provider learn more jon s saxe  ceo founder businessman  profile directorpedianet  list of ceos founders board members and company directors jon s saxe check out list of companies and businesses related to jon s saxe find out jon s saxe address and contact details view other people related to jon s saxe  coworkers colleagues companions etc address companies related to jon s saxe cikcompany namepositioncompany addresssciclone pharmaceuticals incdirector  tower lane suite  foster city 4durect corpdirector 60 bubb road cupertino 685vistagen therapeutics inc 4 allerton avenue south san francisco 40 jon s saxe on the web persons related to jon s saxe  sciclone pharmaceuticals incnamepositioncityabg management ltdhong kongally bridge lb healthcare master fund ltdhong kongally bridge lb management ltdhong kongs p a aptafinromepeter barrettdirector cambridgepeter barrettdirector foster citypeter barrettdirector foster cityjohn d baxterjohn d baxterdirector san mateojohn d baxterdirector foster cityfriedhelm blobelpresident  ceo san mateofriedhelm blobelpresident  ceo foster cityfriedhelm blobelpresident  ceo foster cityedwin c cadmanedwin c cadmandirector san mateoroberto camerinidirector pomezia romeroberto camerinidirector foster cityroberto camerinidirector foster cityclaudio cavazza owner romeclaudio cavazza owner rome italyclaudio cavazza owner romeclaudio cavazza owner romepaolo cavazza owner luganopaolo cavazza owner luganopaolo cavazzaluganopaolo cavazza owner luganopaolo cavazza owner lugano switzerlandpaolo cavazza owner luganopaolo cavazza owner laganonancy t changdirector houstonnancy t changdirector foster citynancy t changdirector foster citychaumiere consultadoria  servicos sdc unipessoal lda funchal  madeiracarey cherngeneral counsel foster citywilson waishun cheungcfo  senior vp finance fremontwilson waishun cheungcfo  senior vp finance foster cityfarmaceutica lda defiantefunchal madeirafarmaceutica lda defiantemadeirafarmaceutica lda defiantemadeiradragon alpha lpbeijinggl capital management gp ltdbeijinggl partners capital management ltdbeijingjere e goyanjere e goyandirector san mateojie jackie guanfoster cityrichard j hawkinsdirector san mateorichard j hawkinsdirector foster cityrichard j hawkinsdirector foster cityrichard j hawkinsdirector foster cityrolf h henelrolf h heneldirector san mateorolf h heneldirector foster cityrolf h heneldirector foster cityivan huiprincipal accounting officer san mateoivan huiprincipal accounting officer foster cityjade park investments ltdbeijingtrevor m jonesdirector reigate surreytrevor m jonesdirector foster cityrobert kingsvp of prod devsupply chain foster cityanthony gregg lapointedirector foster cityanthony gregg lapointedirector gaithersburganthony gregg lapointedirector foster citygregg anthony lapointedirector union citygregg anthony lapointedirector gaithersburgira d lawrencedirector san mateoira d lawrencedirector foster cityira d lawrencedirector foster citybin lihong kongsimon lidirector foster citylanchu liubeijingmark lottershanghaimark lotterceo china operations shanghaimark lotterceo china operations foster cityraymond anthony lowvp finance  controller fremontraymond anthony lowvp finance  controller foster citychuncai menggen counsel  vp compliance shanghaichuncai menggen counsel  vp compliance foster cityisrael riossr vp medical affairs  cmo foster cityisrael rioschief medical officer foster cityisrael rioschief medical officer foster cityalfred r rudolphchief operating officer san mateojon s saxedirector jon s saxedirector foster cityjon s saxedirector foster cityjon s saxedirector san mateohans p schmidpres  mng dir sciclone intl san mateohans p schmidpres  mng dir sciclone intl foster cityhans p schmidpres  mng dir sciclone intl foster cityhans p schmidpres  mng dir sciclone intl foster citydonald r sellerspresident and ceo san mateotau finanziaria spa sigma owner rome italytau finanziaria spa sigma owner rometau finanziaria spa sigma owner rinetau finanziaria spa sigma owner rometau finanziaria spa sigma owner romesa sinafgary titussenior vp finance  cfo foster citygary titussenior vp finance  cfo foster citygary tituscfo  sr vp finance foster citywinnie wingkei tsofoster cityrichard a waldronevp  cfo san mateostephanie wongvp finance and controller foster citydean s woodmandean s woodmandirector san mateodean s woodmandirector san mateodean s woodmandirector foster citydean s woodmandirector foster citylan xievp finance china cfo foster citylan xievp finance china cfo foster citymin yinvp compliance  internal audit foster cityfan yuhong konghong zhaoceo china operations shanghaihong zhaoceo china operations foster citypersons related to jon s saxe  durect corpnamepositioncity april fund lpnew york april fund ltd owner grand caymanarnhold  s bleichroeder advisers llc owner new yorkarnhold  s bleichroeder holdings incnew yorksimon x benitodirector westfieldsimon x benitodirector westfieldsimon x benitodirector cupertinosimon x benitodirector cupertinoterrence f blaschkedirector cupertinoterrence f blaschkedirector cupertinojames e brownpresident  ceo cupertinojames e brownpresident  ceo cupertinojames e brownpresident  ceo cupertinojames e brownpresident  ceo cupertinojames e brownpresident  ceo cupertinomichael d caseydirector cupertinomichael d caseydirector cupertinomichael d caseydirector cupertinomichael d caseydirector cupertinotai wah chanvp pharma research  develp cupertinofirst eagle value in biotechnology master fund ltdnew yorkedward m gillisvp engineering cupertinosteven halladayvp clinical and regulatory cupertinodave hoffmanndirector cupertinodave hoffmanndirector cupertinodave hoffmanndirector cupertinodave hoffmanndirector cupertinomatthew j hoganchief financial officer palo altomatthew j hoganchief financial officer cupertinomatthew j hoganchief financial officer cupertinoli jianvp finance and controller palo altoli jianvp finance and controller cupertinoli jianvp finance  corp controller cupertinojudy r joicesr vp operations  corp qa cupertinopeter langeckercupertinopeter langeckerchief medical officer cupertinojean i liusr vp  general counsel cupertinojean i liusr vp  general counsel jean i liuchief legal officer cupertinopaula v mendenhallsr vp of operations cupertinopaula v mendenhallexec vp of operationsadmin cupertinopaula v mendenhallexec vp of operationsadmin cupertinoandrew miksztalvp pharmaceutical rd cupertinotimothy s nelsonsr vp business  development cupertinoarmand neukermansdirector cupertinoarmand neukermansdirector cupertinoarmand neukermansdirector cupertinoarmand neukermansdirector cupertinoarmand neukermansdirector cupertinoarnand neukernonsdirector cupertinojon s saxedirector jon s saxedirector cupertinojon s saxedirector cupertinojon s saxedirector cupertinojon s saxedirector cupertinothomas a schreckchief financial officer cupertinothomas a schreckchief financial officer cupertinojay sheparddirector cupertinojoseph william stauffercmo and execvp corp strategy cupertinomichael j taylorvp non clinical research cupertinofelix theeuweschairman and cso cupertinofelix theeuweschairman and cso cupertinofelix theeuweschairman and cso cupertinoarthur j tiptonsrvp bioerodible product dev cupertinosu il yumsr vp engineering cupertinosu il yumexec vp pharmrd cupertinosu il yumexec vp pharmrd cupertinopersons related to jon s saxe  vistagen therapeutics incnamepositioncityrice asouth san franciscogregory a bonfiglio south san franciscounderdown briansouth san franciscounderdown briansouth san franciscoallen easley cato owner durhamholding co cato owner durhamjerrold duane dotsoncfo and secretary lake oswegojerrold duane dotsoncfo south san franciscojerrold duane dotsoncfo and secretary south san franciscojerry b gin south san franciscobonfiglio gregorysouth san franciscosnodgrass hsouth san franciscosnodgrass hsouth san franciscodotson jerroldsouth san franciscodotson jerroldsouth san franciscosaxe jonsouth san franciscosaxe jonsouth san franciscostephanie jonesrathdrumstephanie jonespresident rathdrumplatinum long term growth vii llcnew yorkplatinum long term growth vii llc owner new yorka franklin ricevp corporate development south san franciscojon s saxe jon s saxe south san franciscojon s saxe south san franciscosingh shawnsouth san franciscosingh shawnsouth san franciscoshawn singhchief executive officer franklinshawn singhchief executive officer south san franciscoshawn singhchief executive officer south san franciscomark alan smithchief medical officer south san franciscoh ralph snodgrasspreschief scientific officer south san franciscoh ralph snodgrasspreschief scientific officer south san franciscobrian j underdown south san franciscobrian j underdown south san franciscobrian underdownsouth san francisco cancer prevention pharmaceuticals inc announces appointment of jon s saxe to its board of cancer prevention pharmaceuticals inc announces appointment of jon s saxe to its board of directors jul  05  et from cancer prevention pharmaceuticals inc tucson ariz july  05 prnewswire  cancer prevention pharmaceuticals inc cpp today announced that jon s saxe has joined its board of directors saxe brings to cpp many years of experience from the biotechnology pharmaceutical and venture capital industries  he has served as a director of more than 5 companies and currently is a director of several biotechnology companies including sciclone pharmaceuticals nasdaq scln where he is chairman durect corporation nasdaq drrx as well as a number of private companies he was president of pdl biopharma formerly protein design labs and also was president and ceo of synergen a biotechnology company purchased by amgen prior to his work at biotech companies saxe was vice president of licensing and corporate development and head of patent law for hoffmannlaroche inc where he worked for  years   saxe received a bsche from carnegie mellon university a jd from george washington university school of law and a llm from new york university school of law we are honored and excited to have jon saxe join our board said jeff jacob chairman of cpps board of directors  his broad knowledge of the industry and years of experience both as an executive and in corporate governance will serve cpp well as it continues to grow in the coming years  the other members of the board and i are very much looking forward to working with jon about cancer prevention pharmaceuticals inc cpp cpp is developing therapeutics that reduce the risk of cancer  cpps approach has been used with great success in other disease categories such as cardiovascular neurovascular and infectious disease  agents that target predisease states have helped reduce death rates from these conditions by  over the past  years  just as these other prevention therapies represent the largestselling drug classes on the market today cpp believes there is even more potential for therapies that reduce the risk of cancer  cpp is sponsoring a large phase iii trial in colon cancer survivors and a phase iii trial for familial adenomatous polyposis fap an orphan disease that causes hundredstothousands of colon polyps and has a 0 risk of colon cancer unless treated by surgical removal of the colonrectum  cpp is also working collaboratively with nonprofit groups to support clinical trials in the childhood cancer neuroblastoma for the prevention of relapse  additional information on cpp is available at wwwcanpreventcom   source cancer prevention pharmaceuticals inc related links httpwwwcanpreventcom view table fullscreen view table fullscreen journalists and bloggers the news you need when you need it join pr newswire for journalists to access all of the free services designated to make your job easier in need of subject matter experts for your story submit a free profnet request and find the sources you need learn more apr  06  et preview cancer prevention pharmaceuticals completes target enrollment in pivotal phase  clinical trial evaluating cppxsulindac in patients with familial adenomatous polyposis my news release contains wide tables view fullscreen looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search